Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials
Authors:
- Christophe Le TourneauChristophe Le Tourneau
- Maud KamalMKMaud Kamal
- Apostolia-Maria TsimberidouATApostolia-Maria Tsimberidou
- Philippe BedardPBPhilippe Bedard
- Gaëlle PierronGPGaëlle Pierron
- Céline CallensCCCéline Callens
- Etienne RouleauEREtienne Rouleau
- Anne Vincent-SalomonAVAnne Vincent-Salomon
- Nicolas ServantNSNicolas Servant
- Marie AltMAMarie Alt
- Roman RouzierRRRoman Rouzier
- Xavier PaolettiXPXavier Paoletti
Open Access
- 23 November 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 108 (4)
Abstract
With the advent of high-throughput molecular technologies, several precision medicine (PM) studies are currently ongoing that include molecular screening programs and PM clinical trials. Molecular profiling programs establish the molecular profile of patients’ tumors with the aim to guide therapy based on identified molecular alterations. The aim of prospective PM clinical trials is to assess the clinical utility of tumor molecular profiling and to determine whether treatment selection based on molecular alterations produces superior outcomes compared with unselected treatment. These trials use treatment algorithms to assign patients to specific targeted therapies based on tumor molecular alterations. These algorithms should be governed by fixed rules to ensure standardization and reproducibility. Here, we summarize key molecular, biological, and technical criteria that, in our view, should be addressed when establishing treatment algorithms based on tumor molecular profiling for PM trials.Keywords
This publication has 44 references indexed in Scilit:
- Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trialAnnals of Oncology, 2015
- Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing dataBioinformatics, 2014
- Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx StudyPLOS Biology, 2014
- Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trialBritish Journal of Cancer, 2014
- First FDA Authorization for Next-Generation SequencerNew England Journal of Medicine, 2013
- Implementing personalized cancer genomics in clinical trialsNature Reviews Drug Discovery, 2013
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- Pten Haploinsufficiency Accelerates Formation of High-Grade AstrocytomasCancer Research, 2008
- Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.Journal of Clinical Oncology, 1998
- Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor MarkersJNCI: Journal of the National Cancer Institute, 1996